The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer

BACKGROUND: Cancer immunotherapy is being developed as a promising alternative for advanced non-small cell lung cancer (NSCLC). However, novel biomarkers are required to select patients that will benefit from treatment with immune checkpoint inhibitors (ICIs) for a long period of time. The gut micro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Lung Cancer Res
Main Authors: Katayama, Yuki, Yamada, Tadaaki, Shimamoto, Takayuki, Iwasaku, Masahiro, Kaneko, Yoshiko, Uchino, Junji, Takayama, Koichi
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6976345/
https://ncbi.nlm.nih.gov/pubmed/32010563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2019.10.23
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados